WallStSmart

LivaNova PLC (LIVN)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 4424% more annual revenue ($66.57B vs $1.47B). LIVN leads profitability with a 12.8% profit margin vs 4.8%. LIVN appears more attractively valued with a PEG of 0.93. LIVN earns a higher WallStSmart Score of 68/100 (B-).

LIVN

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 6.0Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.35

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LIVNUndervalued (+7.7%)

Margin of Safety

+7.7%

Fair Value

$71.98

Current Price

$78.18

$6.20 discount

UndervaluedFair: $71.98Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$144.85

$62.01 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LIVN3 strengths · Avg: 9.0/10
EPS GrowthGrowth
287.8%10/10

Earnings expanding 287.8% YoY

Debt/EquityHealth
0.279/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.938/10

Growing faster than its price suggests

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

LIVN1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
0.352/10

Distress zone — elevated risk

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : LIVN

The strongest argument for LIVN centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 10.8% demonstrates continued momentum. PEG of 0.93 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : LIVN

The primary concerns for LIVN are Altman Z-Score.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

LIVN carries more volatility with a beta of 0.87 — expect wider price swings.

LIVN is growing revenue faster at 10.8% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LIVN scores higher overall (68/100 vs 36/100) and 10.8% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

LivaNova PLC

HEALTHCARE · MEDICAL DEVICES · USA

LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?